Show simple item record

dc.contributor.authorMerola, E
dc.contributor.authorGordoa, TA
dc.contributor.authorZhang, P
dc.contributor.authorAl-Toubah, T
dc.contributor.authorPelle, E
dc.contributor.authorLiu, M
dc.contributor.authorLaskaratos, F
dc.contributor.authorde Mestier, L
dc.contributor.authorLamarca, Angela
dc.contributor.authorHernando, J
dc.contributor.authorCives, M
dc.contributor.authorvan Leeuwaarde, R
dc.date.accessioned2020-06-15T12:57:42Z
dc.date.available2020-06-15T12:57:42Z
dc.date.issued2020en
dc.identifier.citationMerola E, Gordoa T, Zhang P, Al-Toubah T, Pelle E, Liu M, et al. Somatostatin analogs for pancreatic neuroendocrine tumors: is there any benefit when Ki-67 Is >= 10%? Neuroendocrinology. 2020;110:197-en
dc.identifier.urihttp://hdl.handle.net/10541/622988
dc.language.isoenen
dc.titleSomatostatin analogs for pancreatic neuroendocrine tumors: is there any benefit when Ki-67 Is >= 10%?en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentAzienda Provinciale per i Servizi Sanitari (APSS), Trento, Italyen
dc.identifier.journalNeuroendocrinologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record